The effect of vasopressin treatment on learning in Down's syndrome

J. Eisenberg, Rahel Hamburger-Bar, R. H. Belmaker

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Vasopressin is reported to enhance learning and memory in animal models. In 9 Down's syndrome patients DDAVP, a vasopressin derivative, was administered for 10 days, 40 μg per day, in a double-blind randomized crossover design. A visual-verbal paired associate learning test showed a not significant tendency for benefit with DDAVP. Word List memory was not improved with DDAVP treatment.

Original languageEnglish
Pages (from-to)143-147
Number of pages5
JournalJournal of Neural Transmission
Issue number2
StatePublished - 1 Jun 1984
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'The effect of vasopressin treatment on learning in Down's syndrome'. Together they form a unique fingerprint.

Cite this